| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.59B | 18.44B | 14.91B | 17.43B | 17.23B | 14.63B |
| Gross Profit | 9.66B | 8.98B | 7.05B | 7.78B | 7.87B | 6.81B |
| EBITDA | 7.01B | 6.34B | 4.91B | 5.64B | 5.71B | 4.89B |
| Net Income | 5.81B | 5.36B | 3.83B | 4.51B | 4.61B | 3.91B |
Balance Sheet | ||||||
| Total Assets | 21.90B | 21.35B | 18.74B | 18.78B | 17.20B | 15.89B |
| Cash, Cash Equivalents and Short-Term Investments | 6.69B | 6.39B | 5.85B | 5.37B | 3.66B | 5.73B |
| Total Debt | 4.48B | 4.76B | 4.98B | 5.01B | 5.01B | 5.00B |
| Total Liabilities | 11.71B | 11.48B | 10.21B | 10.57B | 10.92B | 9.86B |
| Stockholders Equity | 10.19B | 9.86B | 8.54B | 8.21B | 6.28B | 6.03B |
Cash Flow | ||||||
| Free Cash Flow | 5.85B | 5.41B | 4.26B | 4.68B | 2.55B | 3.24B |
| Operating Cash Flow | 6.38B | 6.17B | 4.65B | 5.18B | 3.10B | 3.59B |
| Investing Cash Flow | -783.59M | -708.09M | -370.61M | -534.56M | 612.27M | 73.27M |
| Financing Cash Flow | -4.96B | -4.94B | -4.00B | -2.83B | -4.58B | -4.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $410.95B | 40.71 | 51.72% | 0.62% | 24.91% | 39.95% | |
77 Outperform | $194.42B | 34.11 | 62.26% | 0.61% | 25.66% | 46.68% | |
77 Outperform | $202.94B | 29.42 | 35.51% | 0.70% | 4.47% | 0.48% | |
75 Outperform | $152.04B | 36.33 | 99.17% | 0.64% | 22.27% | 45.32% | |
69 Neutral | $31.16B | 28.54 | 11.17% | 2.40% | 8.01% | 10.41% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | $20.66B | 40.72 | 3.00% | 1.50% | -17.33% | -76.71% |
On November 4, 2025, Lam Research Corporation held its annual meeting of stockholders, where key decisions were made, including the approval of a new equity incentive plan, the 2025 Stock Incentive Plan. Additionally, an amendment to the company’s Restated Certificate of Incorporation was approved, limiting the liability of certain officers as permitted by Delaware law. These changes, along with the election of directors and other proposals, reflect Lam Research’s strategic efforts to enhance corporate governance and align executive compensation with shareholder interests.
The most recent analyst rating on (LRCX) stock is a Buy with a $172.00 price target. To see the full list of analyst forecasts on Lam Research stock, see the LRCX Stock Forecast page.
Lam Research Corp’s recent earnings call painted a picture of robust financial performance and strategic positioning, despite facing some regulatory headwinds. The company reported record revenues and strong demand driven by AI and advanced packaging, which are bolstered by significant investments in NAND and DRAM. While challenges such as regulatory impacts in China and tariff pressures exist, the overall sentiment remained positive, emphasizing market leadership and demand growth.
Lam Research Corp faces significant risks from epidemics, pandemics, or disease outbreaks, which can severely impact its business operations and financial performance. Governmental measures to control disease spread, such as quarantines and travel bans, can restrict business activities, leading to facility closures, production delays, and supply chain disruptions. These challenges may result in increased costs, reduced revenues, and decreased profitability, potentially causing material adverse effects on the company’s financial results. Additionally, global health crises can disrupt financial markets and economic stability, affecting customer demand and the company’s access to financing.